


2-[¹²⁵I]-Iodomelatonin N-ACETYL-2-[¹²⁵I]IDO-5-METHOXYTRYPTAMINE

Product Number: NEX236



LOT SPECIFIC INFORMATION

CALCULATED AS OF: 12-May-2025

LOT NUMBER: EG71850

SPECIFIC ACTIVITY:

81.4	TBq/mmol
2200	Ci/mmol
228	MBq/μg
6175	μCi/μg

CONCENTRATION:

8.82	MBq/ml
238.4	μCi/ml

RADIOCHEMICAL PURITY: ≥ 95%

MOLECULAR WEIGHT: 356.3

PACKAGING: 2-[¹²⁵I]Iodomelatonin is shipped in ethanol on dry ice.

SPECIAL INFORMATION: This compound is light sensitive. Exposure to light may hasten decomposition. 2-[¹²⁵I]Iodomelatonin is supplied in a red NENSURE™ vial which contains a U.V. inhibitor.

STABILITY AND STORAGE: 2-[¹²⁵I]Iodomelatonin should be stored at 4°C or lower. Under these conditions the product has been shown to be useful in a receptor assay for at least 12 weeks after fresh lot date.

SPECIFIC ACTIVITY: The initial specific activity of 2-[¹²⁵I]Iodomelatonin is 2200 Ci/mmol (81 TBq/mmol), 6175 μCi/μg (228 MBq/μg). Preparative HPLC is used to separate the unlabeled melatonin from [¹²⁵I]Iodomelatonin. Upon decay, 2-[¹²⁵I]Iodomelatonin undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular or peptide fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on ¹²⁵I decay and decay catastrophe of ¹²⁵I labeled compounds are available.¹⁻⁵

RADIOCHEMICAL PURITY: Initially greater than 95% radiochemically pure as determined by HPLC.

PREPARATIVE PROCEDURE: Melatonin is radioiodinated with no carrier added ¹²⁵I using a proprietary method designed to prevent its oxidation. 2-[¹²⁵I]Iodomelatonin is purified by reversed phase HPLC.

NEX236-R-REV01

Package Size Information

Package Size as of 18-Jul-2025	Volume
1.85 MBq 50 μCi	0.50 ml
3.70 MBq 100 μCi	1.00 ml
925 MBq 250 μCi	2.50 ml

AVAILABILITY: 2-[¹²⁵I]Iodomelatonin is routinely available from stock and is prepared fresh and packaged for shipment on the second Mondays of January, March, May, July, September, and November. Please inquire for larger package sizes.

HAZARD WARNING: This product contains a chemical (s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion and inhalation. It is irritating to the eyes, skin and respiratory tract, is toxic and flammable. Target organs are the eyes, central nervous system, kidneys and liver.

RADIATION UNSHIELDED: 280mR/hr/mCi at vial surface.

REFERENCES:

1. Doyle, V.M., Buhler, F.R., Burgisser, E., *Eur. J. Pharm.* 99 353 (1984).
2. Schmidt, J., *J. Biol. Chem.* 259 1160 (1984).
3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., *J. Biol. Chem.* 257 1418 (1982).
4. Berridge, M.S., Jiang, V.W., Welch, M.J., *Rad. Res.* 82 467 (1980).
5. Charlton, D.E., *Rad. Res.* 107 163 (1986).
6. Laudin, M. and Zisapel, N., *FEBS* 197 9-12 (1986).
7. Niles, L., Pickering, D., Sayer, B., *Bioch. Biophys. Res. Comm.* 147 949-956 (1987).
8. Ducan, M., Takahashi, J., Dubocovich, M., *Eur. J. Pharm.* 132 333-334 (1986).
9. Reppert, S., Weaver, D.R., Rivkees, S.A. and Stopa, E.G., *Science* 242 78-81 (1988).
10. Dubocovich, M., and Takahashi, J., *Proc. Natl. Acad. Sci. U.S.A.* 84 3916-3920 (1987).
11. Weaver, D.R., Nambodiri, M.A.A. and Reppert, S.M., *FEBS* 228 123-127 (1988).
12. Vakkuri, O., Leppaluoto, J. and Vuolteenaho, *Acta Endocrinologica* 106 152-157 (1984).

IODINE-125 DECAY CHART HALF LIFE=60 days

Radiations: Gamma 35.5 keV (7%) , X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
0	1.000	.977	.955	.933	.912	.891	.871	.851	.831	.812
20	.794	.776	.758	.741	.724	.707	.691	.675	.660	.645
40	.630	.616	.602	.588	.574	.561	.548	.536	.524	.512
60	.500	.489	.477	.467	.456	.445	.435	.425	.416	.406
80	.397	.388	.379	.370	.362	.354	.345	.338	.330	.322
100	.315	.308	.301	.294	.287	.281	.274	.268	.262	.256
120	.250	.244	.239	.233	.228	.223	.218	.213	.208	.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

revvity

Revvity, Inc.
940 Winter Street
Waltham, MA 02451 USA

(800) 762-4000
www.revvity.com

For a complete listing of our global offices, visit www.revvity.com
Copyright ©2023, Revvity, Inc. All rights reserved.